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DUPLEX DOPPLER SONOGRAPHIC ASSESSMENT OF THE EFFECTS OF
DIETHYLCARBAMAZINE AND ALBENDAZOLE THERAPY ON ADULT FILARIAL
WORMS AND ADJACENT HOST TISSUES IN BANCROFTIAN FILARIASIS
OMAR HUSSEIN, MAGED EL SETOUHY, EHAB S. AHMED, AMR M. KANDIL, REDA M. R. RAMZY, HANAN HELMY,
AND GARY J. WEIL
Department of Radiology, Department of Community, Environmental, and Occupational Medicine, and Research and Training
Center on Vectors of Diseases, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Infectious Diseases Division,
Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri

Abstract. We used duplex Doppler sonography to assess effects of diethylcarbamazine and albendazole therapy
(DEC/ALB) on adult Wuchereria bancrofti in vivo. The study was performed in clinically normal Egyptian adults with
blood microfilaria counts > 80/mL. Motile adult worms were observed before treatment in dilated scrotal lymphatic
vessels in 28 of 36 men (78%) and over the proximal extremities in 5 of 22 women (23%). Most worm nests were
inactivated in the months following treatment (90% at 12 months). Circulating filarial antigen levels (a marker for living
adult worms) also fell dramatically following treatment. Some men had intrascrotal calcifications and/or non-palpable
hydroceles detectable by ultrasound before they were treated. New hydroceles and intrascrotal calcifications appeared
after treatment in many cases. However, most of these were transient and of no clinical significance. Prevelance rates
for hydrocele and intrascrotal calcifications 24 months after treatment were essentially the same as those prior to
treatment. These results show that DEC/ALB is highly active against adult W. bancrofti. They also suggest that host
responses to dying adult worms are important in the pathogenesis of filarial hydroceles.
ported complete inactivation of 41.5% of worm nests following a 10-day course of treatment with DEC.9 Other studies
reported the presence of subclinical pathology (intrascrotal
calcifications and subclinical hydroceles) in asymptomatic
men with normal clinical examinations10,11 and changes in
these findings following treatment with DEC.10 Faris and others also emphasized the value of using color pulsed-Doppler
to distinguish movement associated with filarial worms from
that associated with the flow of blood in arteries and veins.10
Mand and others concurred with this opinion and posted
video clips illustrating ultrasound findings in African subjects
with Bancroftian filariasis.12
We have recently reported results of a clinical trial that
compared single-dose DEC/ALB with seven daily doses of
the same medications.13 We found that multi-dose therapy
was more effective than single-dose treatment in reducing and
clearing microfilaremia from the blood of infected subjects.
That report also briefly summarized results of ultrasound
studies performed as part of the clinical trial. We now present
a detailed report on ultrasound results from the clinical trial,
with follow-up extending to 24 months after treatment. This
study provided important new information on the effects of
DEC/ALB on adult W. bancrofti and on the appearance and
evolution of local pathology associated with adult worms following treatment.

INTRODUCTION
Bancroftian filariasis is a deforming and disabling disease
caused by the filarial nematode Wuchereria bancrofti. The
most common clinical manifestations of the disease are hydrocele, lymphedema, and elephantiasis. This parasite affects
approximately 100 million people in some 80 countries,
mostly in the developing world.1 Technical advances in diagnosis and treatment led to initiation of a Global Program for
Elimination of Lymphatic Filariasis (reviewed by Ottesen and
others2 and Molyneux and others3). This program comprises
mass drug administration (MDA) of anthelmintics to populations residing in endemic areas to reduce transmission of the
parasite and provision of care and services to people already
affected by the disease. The chemotherapy side of the program calls for MDA to a target population of 1.2 billion
people by the year 2020. The recommended MDA regimen
for all areas outside of sub-Saharan Africa is DEC/ALB
(a single, oral dose of diethylcarbamazine, 6 mg/kg, and albendazole, 400 mg once per year for 4−5 years). Clinical studies have shown that single-dose DEC/ALB treatment is safe
and effective for reducing blood microfilaria (MF) counts for
up to two years.4–6 Results from these trials also suggest that
DEC/ALB has partial activity against adult filarial worms;
circulating filarial antigen levels decreased following singledose DEC/ALB, and some treated subjects developed scrotal
pain and/or subcutaneous nodules that are believed to result
from dying adult worms.4,5 However, more information is
needed on effects of DEC/ALB on adult filarial worms and
on local reactions associated with worm death.
The recognition that medical ultrasound can be used to
visualize adult W. bancrofti in vivo represented a major advance in the field of filariasis.7 Brazilian investigators coined
the term “filarial dance sign” to describe the ultrasound appearance of motile adult filarial worms in dilated lymphatic
vessels in the scrota of infected men. Early studies showed
that the location of worm nests is highly stable in individual
subjects over time.8 Ultrasound can also be used to monitor
effects of treatment on adult filarial worms; one study re-

METHODS
Patient selection. This project was performed as part of a
study of treatment of asymptomatic W. bancrofti infections in
Egyptian subjects. The methods used and results of this trial
have been published in detail.13 Briefly, asymptomatic adults
with night blood MF counts > 80 MF/mL were invited to
participate in the study. Subjects with evidence of clinical
filariasis by physical examination (hydrocele or lymphedema)
or a history of treatment for filariasis in the prior 12 months
were excluded from the study, as were pregnant or lactating
women.
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Randomization and therapy. Eligible subjects were randomly assigned to treatment groups with block stratification
for sex and blood MF count. The trial was not blinded. Study
subjects were treated with either a single oral dose of 6 mg/kg
of DEC citrate (Pharmamed, Zejtun, Malta) plus 400 mg of
ALB (GlaxoSmithKline, Uxbridge, United Kingdom) or with
the same medications daily for seven days. Treatment was
directly observed by study personnel. All subjects were retreated with a single oral dose of DEC (6 mg/kg) and ALB
(400 mg) one year after the first round of treatment.
Tests for W. bancrofti infection. Venous blood samples
were collected between the hours of 9:00 PM and 1:00 AM
before and after treatment for parasitology and serology studies. Microfilariae were detected by membrane filtration (5
M; Nuclepore Corp., Pleasanton, CA) of 1 mL of venous
blood and microscopic examination of stained filters. Filarial
antigenemia, a marker for adult worm infection intensity, was
detected in plasma samples by enzyme immunoassay as previously described in detail.14
Ultrasound methods. Effects of therapy on adult worms
were directly assessed by duplex Doppler sonography. All
examinations were performed by one experienced sonologist
with an ultrasound instrument equipped with a linear phased
array color Doppler transducer (270 SSD Color Doppler,
6 cm linear transducer, 5−7.5 MHz; Toshiba, Tokyo, Japan) as
previously described.10 Inguinal and axillary regions and upper arms and thighs were examined in men and women. Scrotum examinations were performed in men, and breasts were
examined in women. Complete ultrasound examinations were
performed shortly before treatment and at 3, 6, 12, 18, and 24
months after treatment. Abnormal ultrasound findings were
recorded and photographed. Color flow mapping with pulsed
Doppler was used to distinguish the bidirectional movements
of adult filarial worms in dilated lymphatic vessels (dancing
worms) from unidirectional blood flow in veins and arteries.
The diagnosis of hydrocele by ultrasound was based on the
presence of fluid (ⱖ 2 mm thickness) surrounding the testis
and epididymis.15 Subclinical hydroceles were detectable by
ultrasound but not by palpation.
The sonologist studied subjects blindly, without knowing
their treatment assignments. Post-treatment examinations
were first performed without knowledge of prior findings.
Subjects were then re-examined with special attention to areas with abnormalities seen in earlier examinations. Ultrasound findings after treatment were compared with pretreatment results to evaluate loss of motile filarial worms. The
primary endpoint for this study was predefined to be loss of
all motile worms in subjects who had motile worms before

therapy. The secondary endpoint was the percent decrease
(by group) in the number of worm nests observed with motile
adult filarial worms.
Data analysis. Database management and statistical analyses were performed with a statistical software package (SPSS,
Chicago, IL). Proportions were compared by chi-square
analysis or Fisher’s exact test (two-tailed). The Mann-Whitney U test was used to assess the significance of group differences for continuous variables.
Ethical clearance. This study was reviewed and approved
by institutional review boards at Ain Shams University and at
Washington University School of Medicine. Written informed
consent was required for participation in the study.
RESULTS
Pretreatment evaluation. Pretreatment data in Table 1
show that the two treatment groups were generally comparable in terms of infection intensities and pre-treatment ultrasound findings, although filarial antigen levels were significantly higher in the multi-dose treatment group.
Motile filarial worms were observed before therapy in 28 of
36 men (78%) and in 5 of 22 women (23%). All dancing
worms in men were observed in dilated lymphatic vessels
within the scrotum (Figure 1). Approximately equal percentages of worm nests were seen on the right and left sides of the
scrotum (46 and 54%, respectively). Fifty-eight percent (36)
of the nests were located in lymphatic vessels adjacent to the
upper pole of the testis, 39% (24) in the lower pole, and 3%
(2) in the midzone. The number of nests identified in positive
male subjects ranged from 1 to 6 (mean ± SD ⳱ 2.3 ± 1.4,
median ⳱ 2). Subclinical intrascrotal pathology was common
in untreated men (Figure 1); 56% had subclinical hydroceles
(not palpated by examiners) and 50% had intrascrotal calcifications. All dancing worms observed in women were located
in dilated superficial lymphatic vessels over the proximal extremities (left inguinal area in three women and over the
proximal anterior left arm in two women) (Figure 2). Only
one worm nest was observed in each of the women with nests
identified by ultrasound. Intra-lymphatic calcifications were
seen in 4 of 22 women (16.7%).
There was no significant difference in mean MF counts or
parasite antigen levels between subjects with and without visible motile worms, and there was no significant correlation
between the number of nests identified by ultrasound and
either blood MF count or filarial antigen level in the total
study population. However, when the analysis was restricted
to males, these parameters were related, but the correlations

TABLE 1
Pretreatment comparison of treatment groups*
Parameter

Single-dose
group

Multi-dose
group

P

Age, years, mean (SD)
Sex
MF/mL, median (range)
Filarial antigenemia, median (range)
Motile adult worms by US
Lymphatic calcifications
Subclinical hydrocele (men)

36.7 (16.1)
18 M, 10 F
344 (90–3,720)
76.2 (13–1,248)
16/28 (57.1%)
10/28 (37%)
10/18 (56%)

30.4 (10.5)
18 M, 12 F
348 (100–4,431)
178.2 (14–1994)
17/30 (56.7%)
10/30 (33%)
10/18 (56%)

0.14†
0.95‡
0.72†
0.04†
0.97‡
0.93‡
1.0‡

* MF ⳱ microfilariae; US ⳱ ultrasound.
† By Mann-Whitney test.
‡ By chi-square test.
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were not quite statistically significant (MF counts versus
nests, r ⳱ 0.30, P ⳱ 0.08; antigen levels versus nests, r ⳱ 0.31,
P ⳱ 0.06). Interestingly, men with subclinical hydroceles pretreatment had significantly fewer worm nests than men without hydroceles (mean ± SD ⳱ 0.9 ± 0.8 versus 2.9 ± 1.7; P <
0.001). However, age, MF counts, and filarial antigen levels
were not significantly different in men with and without subclinical hydroceles before treatment.
Ultrasound assessment of the effects of DEC/ALB treatment on adult W. bancrofti. Adult worm nest locations were
stable in repeated examinations after treatment; some of the
nests disappeared only after many months. With one or two
exceptions, no nests were seen on post-treatment examinations
that were not observed in the same locations prior to treatment.
Motile adult filarial worms were greatly decreased following therapy in men and women and in both treatment groups.
In some cases with persistent motile worms, the frequency of
movement and amplitude of pulsed Doppler traces were decreased following treatment. The ultrasound appearance of
nests after treatment varied from nest to nest and also
changed over time. In some cases, motile worms were replaced after treatment by small, non-motile echodense objects within dilated lymphatic vessels. Calcifications appeared
in locations formerly occupied by motile worms in some cases.
Lymphatic vessel dilation persisted in some cases, but dilatation completely resolved in other cases.
Table 2 shows categorical data on total inactivation of
worm nests by subject (the predefined primary endpoint for
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the study). Multi-dose treatment was more effective at three
months, but there was no significant difference between the
treatment groups at later time points. Twenty-three of 25
subjects with worm nests visible before treatment had complete inactivation of all worm nests 24 months after treatment
(12 months after the second round of treatment).
Quantitative data on inactivation of adult worm nests are
shown in Figure 3. This was a pre-defined secondary endpoint
of the study. Differences between the two treatment groups
were not statistically significant. For all subjects (both groups
combined), 91%, 90%, and 97% of the worm nests observed
in study subjects prior to treatment were inactive by 6, 12, and
24 months following therapy, respectively. The filarial antigen
test provides a second means of monitoring survival of adult
worms following treatment. There was no significant difference in clearance of antigenemia between the two treatment
groups. Mean ± SD antigen levels were reduced from pretreatment levels by 84.3 ± 9.5% and 91.1 ± 7.2% at 12 and
24 months after treatment, respectively. Total clearance of
filarial antigenemia was observed in 30% and 50% of subjects
12 and 24 months after treatment, respectively.
Ultrasound assessment of changes in scrotal tissues following DEC/ALB treatment. Ultrasound findings in men before
and after treatment are summarized in Table 3, and cases are
shown in Figures 4−6. Subclinical hydroceles and intrascrotal
calcifications were increased after treatment in both groups,
but both of these parameters returned toward pre-treatment
levels at later time points. There was no significant difference

FIGURE 1. Composite of scrotal ultrasound findings in different men before therapy. A, Tortuous, dilated lymphatic vessel with septations,
adjacent to the left testicle. The location of a nest with motile filarial worms is marked. B, Pulsed Doppler trace of a dancing worm. C, Intrascrotal
calcification. D, Small, complex hydrocele with lymphocele.
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FIGURE 2. Large dilated lymphatic vessel with a worm nest (A) and a pulsed Doppler trace (B) taken over the proximal arm of a 19-year-old
woman. The pulsed Doppler trace demonstrates bidirectional flow consistent with a filarial worm nest. The other panels show enlarged lymph
nodes adjacent to subcutaneous fat in the proximal arm (C) and axilla (D) of the same subject.

in the rates of development of hydroceles or calcifications
between the two treatment groups. Fourteen of 16 men without hydroceles prior to treatment developed hydroceles detectable by ultrasound following treatment. These were often
transient, but they persisted to 24 months in some cases; three
men in this group had small palpable hydroceles 24 months
after treatment. Some men with subclinical hydroceles before
treatment had worsening of this finding following treatment.
However, this was often transient, and some men (5 of 16)
with pretreatment subclinical hydroceles had resolution of
this finding 24 months after the first round of treatment.
DISCUSSION
The main objectives of this study were to use duplex Doppler sonography to document effects of DEC/ALB on adult
W. bancrofti and to document effects of treatment on the

appearance and evolution of local pathology associated with
adult worms. However, our pre-treatment observations are
interesting in their own right; high proportions of male subjects in the study had motile adult worms, intrascrotal calcifications, and subclinical hydroceles visible by ultrasound
prior to treatment. These results confirm and expand on results previously reported by our group.10 Motile worms were
also observed in 5 of 22 women studied. This is the first report
of motile worms over the proximal extremities and lymphatic
vessel calcifications in women with filariasis. Most prior studies of ultrasound in filariasis have focused on men. While
dancing worms have been observed in girls,16 they have been
only rarely reported in women; one study reported the presence of a single worm nest (in the breast) in only 1 of 18
microfilaremic women studied in Brazil.17 No breast lesions
were observed in the present study.

TABLE 2
Complete inactivation of adult filarial worms as assessed by ultrasound following diethylcarbamazine/albendazole (DEC/ALB) treatment, by
treatment group*

Single dose
Multidose
Combined
P

Pre-Rx

3 Mo

6 Mo

12 Mo

18 Mo

24 Mo

0/16 (0%)
0/17 (0%)
0/33 (0%)

7/16 (44%)
15/17 (88%)
22/33 (67%)
<0.01†

11/15 (73%)
13/15 (87%)
24/30 (80%)
NS‡

12/15 (75%)
12/14 (86%)
24/29 (83%)
NS‡

12/14 (86%)
10/12 (83%)
22/26 (85%)
NS‡

12/13 (92%)
11/12 (92%)
23/25 (92%)
NS‡

* Subjects were treated with single-dose or multi-dose DEC/ALB at time zero and re-treated with single-dose DEC/ALB 12 months (Mo) later. Data shown are for subjects with motile worms
observed before treatment. P values are for differences between treatment groups. Pre-Rx ⳱ pretreatment; NS ⳱ not significant.
† By chi-square test.
‡ By Fisher’s exact test.
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previously reported, the location of worm nests was stable
over time.8 Most adult worms were killed by both of the
treatment regimens studied, with no significant difference between them. Filarial antigen data also suggested that DEC/
ALB treatment killed most adult filarial worms. Prior studies
have reported that therapy with DEC alone completely inactivated 41.5% of filarial worm nests (as assessed by ultrasound)9 and reduced filarial antigen levels by 40% 12 months
after single dose treatment18 and by 50–70% after multi-dose
treatment.19,20 Our results (90% inactivation of worm nests
and 84% reduction in filarial antigen levels 12 months after
treatment) suggest that DEC/ALB may be more effective
against adult W. bancrofti than DEC alone. However, it is
risky to compare results obtained in trials conducted at different times and in different endemic areas. A new clinical
trial of DEC alone versus DEC/ALB would be required to
directly test this hypothesis.
Ultrasound studies showed that DEC/ALB treatment also
had dramatic effects on host anatomy, especially in men.
Many men developed new hydroceles and/or intrascrotal calcifications following treatment. Most of these changes
were subclinical, but new hydroceles were palpable and persistent in some cases. In addition, some men with subclinical hydroceles prior to treatment had worsening of their hydroceles following treatment. We previously reported development of hydroceles and calcifications in men following
DEC treatment.10 We have no evidence that DEC/ALB
treatment causes more severe clinical or subclinical scrotal
reactions than DEC alone. However, this could be the case if
DEC/ALB is more lethal to adult worms than DEC monotherapy.
The appearance of new hydroceles and intrascrotal calcifications following treatment suggests that inflammatory responses associated with the death of adult filarial worms (with
local release of parasite antigens and intracellular Wolbachia
endosymbiotic bacteria)21 may be involved in the pathogenesis of filarial hydroceles. Thus, DEC/ALB treatment may
accelerate natural processes that lead to hydroceles and intrascrotal calcifications. The presence of calcifications in
some subjects prior to treatment is consistent with this hypothesis. There is no doubt that treatment benefited subjects
by clearing their adult worms, and some subjects had resolution of subclinical hydroceles present at baseline following
therapy. However, treatment was also associated with costs in
some subjects in the form of systemic adverse events (usually
mild and transient)13 and local pathology (usually subclinical
and innocuous). We do not consider these adverse events to

FIGURE 3. Persistence of filarial worm nests (percent of all motile
nests observed pretreatment remaining motile) after treatment, by
treatment group. Subjects were treated with single or multi-dose diethylcarbamazine/albendazole (DEC/ALB) at time zero and retreated with single dose of DEC/ALB 12 months (Mo) later. Data
shown are for subjects with motile worms observed before treatment.
Group differences were not statistically significant (by Mann-Whitney U test).

The absence of motile worms detectable by ultrasound in
some infected men and most women and the weak correlation
between the number of worm nests observed and circulating
filarial antigen levels in men (with no relationship at all in
women) suggest that ultrasound only detects a minority of
adult worms in filariasis patients. We can only speculate on
where the rest of the worms reside. We found that subjects
with subclinical hydroceles prior to treatment had significantly fewer adult worm nests than subjects without hydroceles. This is consistent with findings in our prior study, which
found that dancing worms were uncommon in subjects with
palpable hydroceles.10 Results from both studies are consistent with the hypothesis that death of adult filarial worms is
important in the pathogenesis of filarial hydroceles.
Tobian and others have recently reported that age and filarial antigen levels were significantly correlated with the
presence of hydroceles in untreated men in Papua New
Guinea.11 Our results did not confirm those findings. However, the Papua New Guinea study was population-based and
included amicrofilaremic men and men with palpable hydroceles, while our study was limited to clinically normal subjects
with MF counts > 80/mL.
Ultrasound studies documented dramatic effects of DEC/
ALB therapy on adult filarial worms and host anatomy. As

TABLE 3
Ultrasound assessment of changes in hydrocele and scrotal calcification rates in men following diethylcarbamazine/albendazole (DEC/ALB)
treatment, by treatment group*

Hydroceles
Single dose
Multi dose
Combined
Calcifications
Single dose
Multi dose
Combined

Pre-Rx

3 Mo

6 Mo

12 Mo

18 Mo

24 Mo

10/18 (56%)
10/18 (56%)
20/36 (56%)

18/18 (100%)
16/18 (89%)
34/36 (94%)

11/17 (65%)
12/17 (71%)
23/34 (68%)

10/16 (63%)
8/16 (50%)
18/32 (56%)

7/14 (50%)
10/15 (67%)
17/29 (59%)

9/14 (64%)
5/15 (33%)
14/29 (48%)

8/18 (44%)
10/18 (56%)
18/36 (50%)

11/18 (61%)
13/18 (72%)
24/36 (67%)

16/17 (94%)
13/17 (77%)
29/34 (85%)

13/16 (81%)
10/16 (63%)
23/32 (72%)

10/14 (71%)
9/15 (60%)
19/29 (66%)

8/14 (57%)
7/15 (47%)
15/29 (52%)

* Subjects were treated with single-dose or multi-dose DEC/ALB at time zero and re-treated with single-dose DEC/ALB 12 months (Mo) later.
Group differences were not statistically significant at any time point. Hydrocele frequency in the combined groups was significantly increased over baseline three months after treatment
(P < 0.001). The frequency of scrotal calcifications was significantly increased six months after treatment (P ⳱ 0.04). Pre-Rx ⳱ pretreatment.
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FIGURE 4. This subject had six motile worm nests detected by ultrasound prior to treatment with no hydrocele or calcification. He developed
scrotal discomfort following treatment. Shown are post-treatment findings of a new calcification that developed three months after treatment (A),
a new hydrocele in the right scrotum three months (B) and 18 months following treatment (C), and a left-sided epididymal cyst that developed
after treatment (D). Interestingly, the right-sided hydrocele in this patient was no longer present at 24 months (not shown in the Figure).

be sufficiently severe to outweigh the benefits of MDA, which
is a valuable tool for filariasis elimination programs. However, program managers need to be aware that that these
reactions can occur. Reaction rates are likely to be more common in areas with high infection prevalence rates and high
infection intensities.
In summary, our study confirmed the value of duplex
Doppler sonography for non-invasively visualizing adult

W. bancrofti and for monitoring effects of antifilarial treatment. Therapy with DEC/ALB appears to be highly effective
for killing adult W. bancrofti (approximately 90% at 12
months). This treatment was often followed by de novo development of hydroceles (and worsening of hydroceles already present before treatment in some cases). These results
support the hypothesis that dying adult worms are important
in the pathogenesis of filarial hydroceles.

FIGURE 5. Pretreatment ultrasound appearance (A) and pulsed Doppler tracing (B) from a man with lymphatic vessel dilatation and several
filarial nests identified at the upper pole of the right testis. This subject experienced scrotal discomfort one week after treatment. C, Intrascrotal
calcifications and decreased lymphatic vessel dilation in this area 12 months after treatment with diethylcarbamazine/albendazole.

ULTRASOUND ASSESSMENT OF TREATMENT FOR FILARIASIS
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FIGURE 6. This subject had five filarial worm nests but no hydrocele or calcifications prior to treatment. He developed scrotal discomfort
following treatment. Shown are bilateral hydroceles present three months after treatment (A and B). The hydroceles were smaller but still present
24 months after treatment (C).
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